Literature DB >> 19803723

Between community and hospital: healthcare-associated gram-negative bacteremia among hospitalized patients.

Jonas Marschall1, Victoria J Fraser, Joshua Doherty, David K Warren.   

Abstract

OBJECTIVE: Healthcare-associated, community-acquired bacteremia is a subcategory of community-acquired bacteremia distinguished by recent exposure of the patient to the healthcare system before hospital admission. Our objective was to apply this category to a prospective cohort of hospitalized patients with gram-negative bacteremia to determine differences in the epidemiological characteristics, treatment, and outcome of community-acquired bacteremia; healthcare-associated, community-acquired bacteremia; and hospital-acquired bacteremia.
DESIGN: A 6-month prospective cohort study.
SETTING: A 1,250-bed tertiary care hospital. PATIENTS: Adults hospitalized with gram-negative bacteremia.
RESULTS: Among 250 patients, 160 (64.0%) had bacteremia within 48 hours after admission; 132 (82.5%) of these were considered to have healthcare-associated, community-acquired bacteremia, according to previously published criteria. For patients with healthcare-associated, community-acquired bacteremia, compared with patients with community-acquired bacteremia, malignancies (59 [44.7%] of 132 patients vs 3 [10.7%] of 28 patients; P = .001), open wounds at admission (42 [31.8%] vs 3 [10.7%]; P = .02), and intravascular catheter-related infections (26 [19.7%] vs 0; P = .009) were more frequent and Escherichia coli as a causative agent was less frequent (16 [57.1%] vs 33 [25.0%]; P = .001). There was no difference between these 2 groups in inadequate empirical antibiotic treatment (36 [27.3%] vs 6 [21.4%]; P = .5) and hospital mortality (18 [13.6%] vs 2 [[7.1%]; P = .5). Compared with 90 patients with hospital-acquired bacteremia, patients with healthcare-associated, community-acquired bacteremia had a higher Charlson score (odds ratio [OR], 1.31 [95% confidence interval (CI), 1.14-1.49]) but were less likely to have lymphoma (OR, 0.07 [95% CI, 0.01-0.51]), neutropenia (OR, 0.21 [95% CI, 0.07-0.61]), a removable foreign body (OR, 0.08 [95% CI, 0.03-0.20]), or Klebsiella pneumoniae infection (OR, 0.26 [95% CI, 0.11-0.62]).
CONCLUSIONS: Many cases of gram-negative bacteremia that occurred in hospitalized patients were healthcare associated. The patients differed in some aspects from patients with community-acquired bacteremia and from those with hospital-acquired bacteremia, but not in mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19803723     DOI: 10.1086/606165

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  12 in total

1.  Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI.

Authors:  M N Al-Hasan; J E Eckel-Passow; L M Baddour
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-08       Impact factor: 3.267

2.  Invasion and translocation of uropathogenic Escherichia coli isolated from urosepsis and patients with community-acquired urinary tract infection.

Authors:  B Owrangi; N Masters; A Kuballa; C O'Dea; T L Vollmerhausen; M Katouli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-16       Impact factor: 3.267

3.  Comparative analysis of diguanylate cyclase and phosphodiesterase genes in Klebsiella pneumoniae.

Authors:  Diana P Cruz; Mónica G Huertas; Marcela Lozano; Lina Zárate; María Mercedes Zambrano
Journal:  BMC Microbiol       Date:  2012-07-09       Impact factor: 3.605

4.  MrkH, a novel c-di-GMP-dependent transcriptional activator, controls Klebsiella pneumoniae biofilm formation by regulating type 3 fimbriae expression.

Authors:  Jonathan J Wilksch; Ji Yang; Abigail Clements; Jacinta L Gabbe; Kirsty R Short; Hanwei Cao; Rosalia Cavaliere; Catherine E James; Cynthia B Whitchurch; Mark A Schembri; Mary L C Chuah; Zhao-Xun Liang; Odilia L Wijburg; Adam W Jenney; Trevor Lithgow; Richard A Strugnell
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

5.  Vitamin D's potential to reduce the risk of hospital-acquired infections.

Authors:  Dima A Youssef; Tamra Ranasinghe; William B Grant; Alan N Peiris
Journal:  Dermatoendocrinol       Date:  2012-04-01

6.  Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea.

Authors:  Younghee Jung; Myung Jin Lee; Hye-Yun Sin; Nak-Hyun Kim; Jeong-Hwan Hwang; Jinyong Park; Pyoeng Gyun Choe; Wan Beom Park; Eu Suk Kim; Sang-Won Park; Kyoung Un Park; Hong Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Kyoung-Ho Song; Myoung-Don Oh
Journal:  BMC Infect Dis       Date:  2012-10-03       Impact factor: 3.090

Review 7.  Bloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteria.

Authors:  Vincenzo Russotto; Andrea Cortegiani; Giorgio Graziano; Laura Saporito; Santi Maurizio Raineri; Caterina Mammina; Antonino Giarratano
Journal:  Infect Drug Resist       Date:  2015-08-10       Impact factor: 4.003

8.  Delays in appropriate antibiotic therapy for gram-negative bloodstream infections: a multicenter, community hospital study.

Authors:  Rebekah W Moehring; Richard Sloane; Luke F Chen; Emily C Smathers; Kenneth E Schmader; Vance G Fowler; David J Weber; Daniel J Sexton; Deverick J Anderson
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

9.  Transcriptional activation of the mrkA promoter of the Klebsiella pneumoniae type 3 fimbrial operon by the c-di-GMP-dependent MrkH protein.

Authors:  Ji Yang; Jonathan J Wilksch; Jason W H Tan; Dianna M Hocking; Chaille T Webb; Trevor Lithgow; Roy M Robins-Browne; Richard A Strugnell
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

Review 10.  Classification of healthcare-associated infection: a systematic review 10 years after the first proposal.

Authors:  Teresa Cardoso; Mónica Almeida; N Deborah Friedman; Irene Aragão; Altamiro Costa-Pereira; António E Sarmento; Luís Azevedo
Journal:  BMC Med       Date:  2014-03-06       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.